TY - JOUR
T1 - Chronic Lymphocytic Leukaemia in the Netherlands: Trends in incidence, treatment and survival, 1989-2008
AU - van den Broek, E. C.
AU - Kater, A. P.
AU - van de Schans, S. A. M.
AU - Karim-Kos, H. E.
AU - Janssen-Heijnen, M. L. G.
AU - Peters, W. G.
AU - Nooijen, P. T. G. A.
AU - Coebergh, J. W. W.
AU - Posthuma, E. F. M.
PY - 2012
Y1 - 2012
N2 - We present trends in incidence, early treatment and survival of Chronic Lymphocytic Leukaemia (CLL) between 1989 and 2008, based on population-based data from the Netherlands Cancer Registry. Incidence rates were stable at 5.1 per 100,000 person-years for males, but increased from 2.3 to 2.5 for females, especially for females aged 50-64 years (from 3.6 to 4.3). Patients were less likely to receive chemotherapy within six months, i.e. from 29% to 24% among males and from 25% to 21% among females. Five-year relative survival increased from 61% in 1989-1993 to 70% 2004-2008 for males, and from 71% to 76% for females. The relative excess risk of dying decreased in time to 0.7 (males) and 0.9 (females) in 2004-2008, reference 1989-1993, and increased with age to 2.9 (males) and 1.8 (females) in patients aged 75-94 years, reference 30-64 years. The increasing incidence among females aged 50-64 coincided with the introduction of mass screening for breast cancer, which resulted in a large group of women under increased surveillance and possibly led to increased detection of CLL. The increase in survival might be underestimated due to possible decreased or delayed registration of indolent cases and the retroactive effect of the introduction of new therapies. (C) 2011 Elsevier Ltd. All rights reserved
AB - We present trends in incidence, early treatment and survival of Chronic Lymphocytic Leukaemia (CLL) between 1989 and 2008, based on population-based data from the Netherlands Cancer Registry. Incidence rates were stable at 5.1 per 100,000 person-years for males, but increased from 2.3 to 2.5 for females, especially for females aged 50-64 years (from 3.6 to 4.3). Patients were less likely to receive chemotherapy within six months, i.e. from 29% to 24% among males and from 25% to 21% among females. Five-year relative survival increased from 61% in 1989-1993 to 70% 2004-2008 for males, and from 71% to 76% for females. The relative excess risk of dying decreased in time to 0.7 (males) and 0.9 (females) in 2004-2008, reference 1989-1993, and increased with age to 2.9 (males) and 1.8 (females) in patients aged 75-94 years, reference 30-64 years. The increasing incidence among females aged 50-64 coincided with the introduction of mass screening for breast cancer, which resulted in a large group of women under increased surveillance and possibly led to increased detection of CLL. The increase in survival might be underestimated due to possible decreased or delayed registration of indolent cases and the retroactive effect of the introduction of new therapies. (C) 2011 Elsevier Ltd. All rights reserved
U2 - https://doi.org/10.1016/j.ejca.2011.06.053
DO - https://doi.org/10.1016/j.ejca.2011.06.053
M3 - Article
C2 - 21795040
SN - 0959-8049
VL - 48
SP - 889
EP - 895
JO - European journal of cancer (Oxford, England
JF - European journal of cancer (Oxford, England
IS - 6
ER -